Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Interventional rTMS for Improving Social Perception in Autism (IRIS-gaze)

17. September 2026 aktualisiert von: Assistance Publique - Hôpitaux de Paris

Autism spectrum disorder (ASD) is a neurodevelopmental condition mainly characterized by difficulties in social interaction and social communication. Over the last 30 years, neuroimaging studies have identified anatomical and functional abnormalities localized in the superior temporal sulcus (STS) in individuals with ASD. The STS is a brain region that plays a central role in the perception and interpretation of social information. These findings make the STS a particularly relevant target for developing new therapeutic approaches aimed at improving social difficulties associated with ASD.

The IRIS study aims to evaluate the effects of a non-invasive neuromodulation technique, transcranial magnetic stimulation (TMS), on social perception and social behavior in pre-adolescents and adolescents with ASD aged 10 to 17 years. The stimulation protocol, called intermittent theta-burst stimulation (iTBS), will target the right posterior STS. Previous studies conducted by the research team have established the feasibility and good tolerability of this approach in young adults with ASD.

This is a randomized, double-blind, placebo-controlled clinical trial involving 16 participants and using a crossover design. Each participant will receive both active and placebo stimulation, in a randomized order, with an interval of approximately three months between the two periods. Each treatment period will consist of five sessions per day for four consecutive days, for a total of 20 sessions.

The effects of the intervention on social perception and behavior will be objectively assessed using eye-tracking during the viewing of social scenes. Brain MRI will also be used to investigate potential changes in brain function, connectivity, and structure. In addition, clinical scales completed with the parents will be used to assess social behavior and overall functioning.

The study will therefore determine whether an accelerated TMS protocol targeting a brain region involved in social cognition can improve social perception and behavior in young people with ASD, while also assessing its safety, tolerability, and effects on brain function.

Studienübersicht

Detaillierte Beschreibung

Autism spectrum disorder (ASD) is a neurodevelopmental condition mainly characterized by persistent difficulties in social communication and interaction, together with restricted and repetitive patterns of behavior. Despite substantial progress in understanding the neurobiological mechanisms underlying ASD, therapeutic options specifically targeting core social difficulties remain limited. Non-invasive brain stimulation techniques, including transcranial magnetic stimulation (TMS), therefore represent a promising approach for investigating and potentially modulating neural networks involved in social functioning.

Neuroimaging studies have consistently identified structural and functional abnormalities localized in the superior temporal sulcus (STS) in individuals with ASD. The STS is a key component of the social brain network and is involved in the processing and integration of socially relevant information, including faces, gaze, voices, biological motion, and other dynamic social cues. Functional and structural abnormalities of this region, as well as altered connectivity between the STS and other components of the social brain network, have been reported in ASD. These findings provide the neurobiological rationale for targeting the STS in the present study.

Previous work by our research team has investigated whether modulation of the right posterior STS (pSTS) using TMS can influence social perception. A first study in typically developing adults established a causal relationship between modulation of pSTS activity and changes in visual exploration of socially relevant information. Subsequent studies in young adults with ASD demonstrated the feasibility and good tolerability of excitatory intermittent theta-burst stimulation (iTBS) targeting the right pSTS. More recently, a pilot randomized, double-blind, sham-controlled clinical trial in young adults with ASD evaluated repeated iTBS sessions targeting this region. The intervention was feasible and well tolerated, and preliminary findings suggested differential changes in social behavior following active compared with sham stimulation. These findings support further investigation of this approach using a more intensive stimulation protocol.

The IRIS-gaze study investigates an accelerated iTBS protocol targeting the right pSTS in pre-adolescents and adolescents with ASD. Adolescence represents a developmental period characterized by substantial brain plasticity and may therefore constitute a particularly relevant period for neuromodulatory interventions. Accelerated TMS protocols, in which several stimulation sessions are administered each day over a limited number of days, are designed to induce cumulative neuroplastic effects while substantially reducing the overall duration of treatment compared with conventional repeated TMS schedules.

IRIS-gaze is an interventional, randomized, double-blind, sham-controlled crossover clinical trial. Sixteen participants will receive both active and sham stimulation in a randomized order. Each treatment period consists of five iTBS sessions per day for four consecutive days, for a total of 20 sessions per treatment period. The two treatment periods are separated by a washout period of approximately three months (3 months ± 2 weeks), selected to minimize potential carry-over effects between active and sham stimulation. The crossover design allows each participant to serve as his or her own control, thereby reducing the influence of inter-individual variability, and insures that all participants receive the active condition.

Stimulation will be performed using a MAGSTIM RAPID2® stimulator and a cooled figure-of-eight coil. The right pSTS target will be individually identified from each participant's structural MRI and localized during stimulation using MRI-guided neuronavigation. Before stimulation, the individual motor threshold will be determined using single-pulse TMS. Each iTBS session will deliver 1,800 pulses, consisting of bursts of three pulses at 50 Hz repeated at 5 Hz, delivered in 2-second trains separated by 8-second intervals. Five sessions will be administered each day, separated by 50-minute intervals.

The sham condition will follow the same schedule and procedures as active stimulation. A dedicated sham coil will reproduce the appearance, acoustic characteristics, and sensory experience of active stimulation without inducing cortical stimulation. Investigators conducting MRI, eye-tracking, and clinical assessments will remain blinded to stimulation condition.

A multimodal evaluation strategy will be used to characterize potential effects of the intervention. Social visual behavior will be objectively assessed using infrared eye-tracking during the presentation of dynamic social stimuli. Brain MRI will complement the behavioral assessment by investigating potential changes in cerebral perfusion, resting-state functional connectivity, and white-matter microstructure. Clinical assessments completed with parents will provide complementary information regarding social behavior and overall functioning. Assessments will be performed at predefined time points throughout the crossover protocol, allowing comparison of changes associated with active and sham stimulation.

The study combines targeted non-invasive neuromodulation with objective behavioral measurements and multimodal neuroimaging to investigate the effects of accelerated iTBS on neural systems involved in social functioning in young people with ASD. Beyond evaluating the potential clinical relevance of this approach, IRIS-gaze aims to improve understanding of the relationship between modulation of the right pSTS, brain network plasticity, and social behavior in ASD. Ultimately, this study could pave the way for a novel non-invasive therapeutic approach aimed at improving social functioning in children and adolescents with ASD.

Studientyp

Interventionell

Einschreibung (Geschätzt)

16

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

      • Paris, Frankreich, 75013
        • Plateforme CENIR_PANAM au centre de Neuro Imagerie de recherche à l' " Institut du Cerveau " (ICM)
        • Kontakt:
      • Paris, Frankreich, 75015
        • Hôpital Necker - Enfants Malades - Service de radiologie pédiatrique
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Diagnosis of Autism Spectrum Disorder (ASD) according to DSM-5 criteria and confirmed by the Autism Diagnostic Interview-Revised (ADI-R).
  • Aged 10 to 17 years, inclusive.
  • Able to undergo an MRI examination.
  • Affiliated with or beneficiary of a social
  • Affiliated with or beneficiary of a social security system.
  • Written informed consent provided by the participant and/or their legal representative

Exclusion Criteria:

  • Presence of epilepsy or a history of seizures.
  • Contraindication to TMS, including personal or family history of epilepsy, history of craniotomy, cardiac pacemaker, intraocular or intracerebral metallic foreign body, cochlear implant, cardiac valve or metallic surgical material, or any material likely to concentrate radiofrequency pulses, and open wounds on the head or irritated scalp.
  • Contraindication to MRI, including cardiac pacemaker, intracorporeal metallic foreign body, or occupational exposure to metallic particles.
  • Presence of a neurological condition (epilepsy, cerebral palsy, neuromuscular disease, neurological sequelae of brain injury, or central nervous system malformation)
  • Initiation, discontinuation, or modification of treatment with neuroleptics or benzodiazepines during the previous month (unstable treatment)
  • Pregnancy or breastfeeding (based on patient/parental interview).
  • Current participation in another clinical trial.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: TMS / sham
The active TMS session takes place during the first series. The second series is a sham series
2 series of 5 TMS applied each day, during 4 consecutive days : active or sham according randomization

For all patients, each MRI scan will include:

  • an ASL MRI to measure cerebral blood flow (CBF) at rest,
  • a resting-state functional MRI (rs-fMRI) to measure functional connectivity,
  • a diffusion-weighted MRI (DWI-MRI) to assess the microstructural integrity of the white matter.

The total duration of each MRI scan will be approximately 30 minutes, and no injections or premedication will be used.

Eye-tracking technology records eye movements and tracks a participant's gaze while they view stimuli presented on a screen, by analyzing images of the eye captured by an infrared camera.
A Social Responsiveness Scale, Second Edition (SRS-2), Autism Behavior Checklist (ABC) and Clinical Global Impressions (CGI) will be used for assessment of Changes Induced by TMS on Social Behavior and Autistic Symptoms before the start of TMS sessions and during the 24 hours following the last stimulation session.
Experimental: Sham / TMS
The active TMS session takes place during the second series. The first series is a sham series
2 series of 5 TMS applied each day, during 4 consecutive days : active or sham according randomization

For all patients, each MRI scan will include:

  • an ASL MRI to measure cerebral blood flow (CBF) at rest,
  • a resting-state functional MRI (rs-fMRI) to measure functional connectivity,
  • a diffusion-weighted MRI (DWI-MRI) to assess the microstructural integrity of the white matter.

The total duration of each MRI scan will be approximately 30 minutes, and no injections or premedication will be used.

Eye-tracking technology records eye movements and tracks a participant's gaze while they view stimuli presented on a screen, by analyzing images of the eye captured by an infrared camera.
A Social Responsiveness Scale, Second Edition (SRS-2), Autism Behavior Checklist (ABC) and Clinical Global Impressions (CGI) will be used for assessment of Changes Induced by TMS on Social Behavior and Autistic Symptoms before the start of TMS sessions and during the 24 hours following the last stimulation session.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in eye-gaze pattern during social visual exploration
Zeitfenster: 24 hours after each 4-day iTBS treatment block (active and sham)
Change in visual exploration of socially relevant information following active versus sham iTBS targeting the right posterior superior temporal sulcus (pSTS), assessed using eye-tracking during the presentation of social scenes. Eye-gaze patterns will be quantified using predefined areas of interest (AOIs), with fixation data extracted using Tobii eye-tracking technology and normalized for statistical analysis.
24 hours after each 4-day iTBS treatment block (active and sham)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in resting cerebral blood flow
Zeitfenster: 24 hours after each 4-day iTBS treatment block (active and sham)
Change in rest cerebral blood flow (CBF) following active versus sham iTBS targeting the right posterior superior temporal sulcus, assessed using arterial spin labeling magnetic resonance imaging (ASL-MRI).
24 hours after each 4-day iTBS treatment block (active and sham)
Change in resting-state functional connectivity
Zeitfenster: 24 hours after each 4-day iTBS treatment block (active and sham)
Change in resting-state functional brain connectivity following active versus sham iTBS targeting the right posterior superior temporal sulcus, assessed using resting-state functional magnetic resonance imaging (rs-fMRI).
24 hours after each 4-day iTBS treatment block (active and sham)
Change in white matter microstructure
Zeitfenster: 24 hours after each 4-day iTBS treatment block (active and sham)
Change in white matter microstructural integrity following active versus sham iTBS targeting the right posterior superior temporal sulcus, assessed using diffusion-weighted magnetic resonance imaging (DWI-MRI)
24 hours after each 4-day iTBS treatment block (active and sham)
Change in social responsiveness assessed by the SRS-2
Zeitfenster: 24 hours after each 4-day iTBS treatment block (active and sham)
Change in social functioning following active versus sham iTBS, assessed using the Social Responsiveness Scale, Second Edition (SRS-2), completed with the participant's parents.
24 hours after each 4-day iTBS treatment block (active and sham)
Change in autism-related behaviors assessed by the ABC
Zeitfenster: 24 hours after each 4-day iTBS treatment block (active and sham)
Change in autism-related behaviors following active versus sham iTBS, assessed using the Autism Behavior Checklist (ABC), completed with the participant's parents.
24 hours after each 4-day iTBS treatment block (active and sham)
Change in global clinical functioning assessed by the CGI
Zeitfenster: 24 hours after each 4-day iTBS treatment block (active and sham)
Change in overall clinical functioning following active versus sham iTBS, assessed using the Clinical Global Impressions (CGI).
24 hours after each 4-day iTBS treatment block (active and sham)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Nathalie BODDAERT, MD, PhD, Assistance Publique - Hôpitaux de Paris
  • Studienstuhl: Monica ZILBOVICIUS, PhD, INSERM INSERM ERL "Trajectoires Développementales en Psychiatrie" Service de Radiologie Pédiatrique Hospital Necker Enfants Malades

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Oktober 2026

Primärer Abschluss (Geschätzt)

1. November 2028

Studienabschluss (Geschätzt)

1. Januar 2029

Studienanmeldedaten

Zuerst eingereicht

11. September 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

17. September 2026

Zuerst gepostet (Tatsächlich)

18. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

17. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren